1) A 40-year old female patient is being followed up for diabetes mellitus. She is currently on Metformin 1 gram twice a day and has been tolerating it well for about six months. Her hemoglobin A1c a week ago was 8.9%. The plan is to initiate liraglutide therapy in addition to the metformin. Which of the following statements is true with regards to liraglutide. ▪ Liraglutide may be stored in the refrigerator or freezer prior to first use. ▪ The brand name is Bydureon ▪ Nausea and/or vomiting are common side effects of therapy ▪ It should be administered intramuscularly into the upper arm. 2) The patient who takes insulin has just been prescribed a beta blocker drug. You recognize that the interaction of the beta blocker and the insulin may have which result? ▪ Decreased activity of the beta blocker drug ▪ Enhanced activity of the beta blocker drug ▪ Masked signs of hypoglycemia ▪ Masked signs of hyperglycemia 3) The drug of choice for type 2 diabetics is metformin. Metformin: ▪ Increases intestinal uptake of glucose ▪ Decreases glycogenolysis by the liver ▪ Increases the release of insulin from beta cells ▪ Prevents weight gain associated with hyperglycemia 4) Which classification of oral hypoglycemic drugs decreases hepatic glucose production and increases insulin sensitivity and peripheral glucose uptake? ▪ Sulfonylureas (glyburide) ▪ Meglitinides (glinides) ▪ Biguanide (metformin) ▪ alpha-glycosidase inhibitor (miglitol) 5) A breast-feeding mother is seen in your clinic wanting contraceptive and plans on breast-feeding for a year. What is an inappropriate choice for this patient? ▪ Depo-Provera 150mg IM every 3 months ▪ Progestin-only OC ▪ Combination OC ▪ Intrauterine device 6) Which of the following is (are) true about oral contraceptives (OCs)? ▪ Estrostep, Ortho Tri-Cyclen, Beyaz, and YAZ are approved for managing acne in women ▪ All the answrs are correct ▪ OCs favorably affect menstrual symptoms: cramps reduction, reduced menstrual flow volume and duration. ▪ OCs decrease the risk for several disorders, including ovarian cancer, endometrial cancer, ovarian cysts, pelvic inflammatory disease, benign breast disease.